奥马珠单抗联合变应原免疫治疗在儿童重度过敏性哮喘中的应用进展  

Progress in application of omalizumab combined with allergen immunotherapy to the treatment of children with severe allergic asthma

作　　者：苟思敏 邹江龙 李元霞[1] 贾鲲鹏[1] 李芳 杨翔悦 GOU Simin;ZOU Jianglong;LI Yuanxia;JIA Kunpeng;LI Fang;YANG Xiangyue(Department of Pediatrics,Yan′an University Affiliated Hospital,Yan′an 716000,Shaanxi Province,China;Ansai District Maternal and Child Health Center,Yan′an 716000,Shaanxi Province,China)

机构地区：[1]延安大学附属医院儿科,陕西延安716000 [2]延安市安塞区妇幼保健院,陕西延安716000

出　　处：《新乡医学院学报》2025年第3期248-252,F0003,共6页Journal of Xinxiang Medical University

基　　金：陕西省卫生健康科研基金项目(编号:2018D081);延安市科技计划项目(编号:2022SLSFGG-037)。

摘　　要：奥马珠单抗(OMA)是一种重组人源化抗免疫球蛋白(Ig)E单克隆抗体,可治疗IgE介导的持续性过敏性哮喘,已有大量临床试验及案例证实了其有效性和安全性。变应原免疫治疗是一种免疫介导的生物治疗方法,其主要针对IgE介导的变态反应性疾病,是目前基于病因治疗且对疾病病程产生积极影响的治疗方法。研究发现,在重度过敏性哮喘儿童中,联合应用OMA和变应原免疫治疗可有效控制症状,减轻病情严重程度,但目前相关临床数据仍较有限。本文现就OMA联合变应原免疫治疗在儿童重度过敏性哮喘中的应用予以综述,以期为儿童哮喘的临床治疗提供参考。Omalizumab(OMA)is a recombinant humanized anti-immunoglobulin(Ig)E monoclonal antibody,which can be used to treat IgE-mediated persistent allergic asthma.There are extensive clinical trials and cases proving the effectiveness and safety of OMA.Allergen immunotherapy is a kind of immune-mediated biological therapy,which mainly aims at IgE-mediated allergic diseases and is a therapy based on etiology that can have a positive effect on the long-term course of the disease.Studies have shown that in children with severe allergic asthma,the combined use of OMA and allergen immunotherapy can effectively control symptoms and reduce disease severity,but related clinical data are still rare.In this article,the joint application of OMA and allergen immunotherapy in children with severe allergic asthma was reviewed to provide reference for clinical treatment of pediatric asthma.

关 键 词：儿童重度过敏性哮喘 奥马珠单抗 变应原免疫治疗 联合应用 

分 类 号：R725.6[医药卫生—儿科]